^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CEP290 mutation

    i
    Other names: CEP290, Centrosomal Protein 290, Cancer/Testis Antigen 87, BBS14, NPHP6, Bardet-Biedl Syndrome 14 Protein, Centrosomal Protein Of 290 KDa, Centrosomal Protein 290kDa, Meckel Syndrome, Type 4, Tumor Antigen Se2-2, Nephrocystin-6, JBTS5, LCA10, SLSN6, POC3, POC3 Centriolar Protein Homolog (Chlamydomonas), Monoclonal Antibody 3H11 Antigen, POC3 Centriolar Protein Homolog, Prostate Cancer Antigen T21, Bardet-Biedl Syndrome 14, CTCL Tumor Antigen Se2-2, Joubert Syndrome 5, Nephrocytsin-6
    Entrez ID:
    80184
    6ms
    Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Ocugen | Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CEP290 (Centrosomal Protein 290)
    |
    CEP290 mutation
    3years
    [VIRTUAL] Characterization of synergistic selinexor combinations with dexamethasone, pomalidomide, elotuzumab, and daratumumab in primary MM cells (AACR 2021)
    We observed ex vivo synergy between SELI and DEX, POM, ELO and DARA, and identified expression signatures and mutations associated with response to these agents. Ongoing analysis of additional samples is being performed to validate these results.
    IO biomarker
    |
    SDC1 (Syndecan 1) • XPO1 (Exportin 1) • BCL7A (BAF Chromatin Remodeling Complex Subunit BCL7A) • CEP290 (Centrosomal Protein 290)
    |
    BCL7A mutation • CEP290 mutation
    |
    Xpovio (selinexor) • Darzalex (daratumumab) • pomalidomide • Empliciti (elotuzumab)